Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
Panagiotis Skendros, Georgios Germanidis, Dimitrios C. Mastellos, et al.
Science Advances (2022) Vol. 8, Iss. 33
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Humoral Innate Immunity and Acute-Phase Proteins
Alberto Mantovani, Cecília Garlanda
New England Journal of Medicine (2023) Vol. 388, Iss. 5, pp. 439-452
Open Access | Times Cited: 134
A guide to complement biology, pathology and therapeutic opportunity
Dimitrios C. Mastellos, George Hajishengallis, John D. Lambris
Nature reviews. Immunology (2023) Vol. 24, Iss. 2, pp. 118-141
Closed Access | Times Cited: 95
Genetic justification of COVID‐19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm
Panagiotis G. Asteris, Amir H. Gandomi, Danial Jahed Armaghani, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 4
Open Access | Times Cited: 13
The complement cascade in lung injury and disease
Maria G. Detsika, Kostas Palamaris, Ioanna Dimopoulou, et al.
Respiratory Research (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 8
Emerging role of complement in COVID-19 and other respiratory virus diseases
Mark Xiao, Calder Ellsworth, Xuebin Qin
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 7
A B1a–natural IgG–neutrophil axis is impaired in viral- and steroid-associated aspergillosis
Nicole Sarden, Sarthak Sinha, Kyle Potts, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 674
Closed Access | Times Cited: 30
Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery
Christina Lamers, Daniel Ricklin, John D. Lambris
American Journal of Hematology (2023) Vol. 98, Iss. S4
Open Access | Times Cited: 17
Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial
Djillali Annane, Sean J. Pittock, Hrishikesh S. Kulkarni, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 12, pp. 1051-1063
Open Access | Times Cited: 17
Hyper‐inflammation and complement in COVID‐19
Bruno Garcia Pires, Rodrigo T. Calado
American Journal of Hematology (2023) Vol. 98, Iss. S4
Open Access | Times Cited: 17
Immunobiology and immunotherapy of COVID-19
Kenneth Lundström
Progress in molecular biology and translational science (2025)
Closed Access
Pneumonia: Recent Updates on Diagnosis and Treatment
Mubashir Ali Khan, Awais Bajwa, Syed Hussain
Microorganisms (2025) Vol. 13, Iss. 3, pp. 522-522
Open Access
Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy
Weiyue Zhang, Baoqing Pei, Yifan Zhou, et al.
Aging and Disease (2025)
Open Access
Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2
Prabhat Kumar Purbey, Koushik Roy, Sandeep Gupta, et al.
Molecular Immunology (2023) Vol. 156, pp. 111-126
Open Access | Times Cited: 13
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome
А. С. Чернов, Maksim V. Rodionov, В. А. Казаков, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Complement system activation: bridging physiology, pathophysiology, and therapy
Élie Azoulay, Julien Zuber, Ahmed Aziz Bousfiha, et al.
Intensive Care Medicine (2024) Vol. 50, Iss. 11, pp. 1791-1803
Closed Access | Times Cited: 4
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors
Christina Lamers, Xiaoguang Xue, Martin Smieško, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Daniel Ricklin
European Journal of Immunology (2024) Vol. 54, Iss. 12
Open Access | Times Cited: 3
A complement atlas identifies interleukin-6–dependent alternative pathway dysregulation as a key druggable feature of COVID-19
Karel Van Damme, Levi Hoste, Jozefien Declercq, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 710
Open Access | Times Cited: 9
Targeting Neutrophil Extracellular Traps for Stroke Prognosis: A Promising Path
Eirini Liaptsi, Ermis Merkouris, Efthymia Polatidou, et al.
Neurology International (2023) Vol. 15, Iss. 4, pp. 1212-1226
Open Access | Times Cited: 9
Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways
Sophia J. Sonnentag, Arthur Dopler, Katharina Kleiner, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 4, pp. 105784-105784
Open Access | Times Cited: 2
Proteomic analysis of lung responses to SARS-CoV-2 infection in aged non-human primates: clinical and research relevance
Andreu Garcia‐Vilanova, Anna Allué‐Guardia, Nadine M. Chacon, et al.
GeroScience (2024) Vol. 46, Iss. 6, pp. 6395-6417
Closed Access | Times Cited: 2
The complement model disease paroxysmal nocturnal hemoglobinuria
Christoph Q. Schmidt, Britta Höchsmann, Hubert Schrezenmeier
European Journal of Immunology (2024) Vol. 54, Iss. 11
Open Access | Times Cited: 2
The complement system: A key player in the host response to infections
Archana Jayaraman, Sarah Walachowski, Markus Bosmann
European Journal of Immunology (2024) Vol. 54, Iss. 11
Open Access | Times Cited: 2
Enhanced complement activation and MAC formation accelerates severe COVID-19
Calder Ellsworth, Zhen Chen, Mark Xiao, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Targeted genotyping of COVID-19 patients reveals a signature of complement C3 and factor B coding SNPs associated with severe infection
Stefanos A. Tsiftsoglou, Eleni Gavriilaki, Tasoula Touloumenidou, et al.
Immunobiology (2023) Vol. 228, Iss. 2, pp. 152351-152351
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top